Once again Leo drops an easter egg for those who a
Post# of 72440
"Finally, Brilacidin has anti-inflammatory properties that may accelerate and promote clinical healing."
In the past he told us that performing the B Ulcerative Proctitis trial is contingent on the B-Oral Mucositis trial demonstrating the anti-inflammatory properties. We know that they are moving forward with plan for that trial in March. Now he is flat telling us that B HAS that property in this PR!!
Folks, we have an obvious blockbuster of a drug platform in B. IMO it is only a matter of when, not if, that CTIX secures a lucrative deal on B.